Form 4: Viatris Inc. Executive Anthony Mauro Reports Stock Transactions Following RSU Vesting

Anthony Mauro, President of Developed Markets at Viatris Inc., reports the acquisition and disposal of VTRS common stock related to the vesting of restricted stock units (RSUs) and performance restricted stock units (PRSUs), as well as the withholding of shares for tax liabilities.

Summary

• On March 2nd, 3rd, and 4th, 2024, Anthony Mauro, President of Developed Markets at Viatris Inc., engaged in transactions involving VTRS common stock.
• These transactions primarily involved the vesting of performance restricted stock units (PRSUs) and restricted stock units (RSUs).
• Mauro acquired shares upon the vesting of these units and simultaneously disposed of shares to cover tax liabilities associated with the vesting.
• The transactions also included the vesting of dividend equivalent units (DEUs) that accrued with respect to previously granted RSUs.
• As a result of these transactions, Mauro's directly held Viatris common stock holdings changed, reflecting the acquisition of shares from vesting and the disposal of shares for tax obligations.
• Mauro's separation from Viatris on April 1, 2024, will result in the forfeiture of certain RSUs that would have vested in the future.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock transactions related to executive compensation. It doesn't contain overtly positive or negative information, but the forfeiture of RSUs upon departure could be seen as slightly negative.

Negatives

• Anthony Mauro's upcoming separation from Viatris on April 1, 2024, will result in the forfeiture of certain unvested RSUs.

Future Outlook

The document indicates that Anthony Mauro is separating from Viatris on April 1, 2024, which will result in the forfeiture of certain RSUs that would have vested in the future.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the transactions of company insiders, which can be useful for investors monitoring management's alignment with shareholder interests.

Comparison to Industry Standards

• Executive compensation packages including RSUs and PRSUs are standard practice in the pharmaceutical industry.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Pfizer use similar equity-based compensation to incentivize executives.
• The vesting schedules and performance metrics associated with these units are typically aligned with long-term company performance goals, which is a common benchmark.

Management Changes

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders, as they provide insight into management's perspective on the company's stock.
• Employees may be affected by the departure of Anthony Mauro and any subsequent organizational changes.

Key Dates